T cell-based HIV vaccine candidate demonstrates positive results

The question of whether or not to continue to pursue the development of T-cell-based HIV-1 vaccines has been a source of controversy following last year's widely publicized failure of the field's most promising candidate, a vaccine developed by Merck known as V520.

Read the whole article on Physorg

More from Physorg